22201-Peritoneal Cancer-NA-1558

Peritoneal Cancer

IMGN853-0421: Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

  • Details

ClinicalTrials.gov ID: NCT05445778
Diagnosis Type: NA
USOR Number:

  • Address

12123 SW 69th Avenue
Tigard, OR 97223
P: (971) 708-7600

Search by practice name, trial titles, indicators and specific disease types.

Find a Location

With more than 2,500 physicians and over 600 treatment locations across the country, the advanced cancer care you need may be available right in your local community from a practice in The US Oncology Network. Search to see if there is a center near you.